

## Result from study using Monivent Neo100 will be presented at the PAS meeting in Washington

**Dr Michael Wagner from the Medical University of Vienna will present results from the study “Optimization of ventilation strategies in preterm and term infants in a single-center intervention study” at the Pediatric Academic Societies (PAS) annual meeting in Washington April 27 – May 1. This is the largest study conducted where Monivent Neo100 has been used.**

A total of 90 preterm and term newborns were included in the study. Ventilations were either recorded with the Neo100 monitor hidden (control group) or the Neo100 visible to caregivers and providing real-time feedback on ventilation quality (intervention group). The hypothesis was that using a respiratory function monitor (Neo100) during positive pressure ventilation of infants will lead to more frequent corrections of tidal volumes outside the recommended range and to more frequent adjustments of the face mask to reduce leak. The PAS meeting connects thousands of pediatricians and other health care providers worldwide and is produced through the partnership of four leading pediatric associations; the American Academy of Pediatrics (AAP), the Academic Pediatrics Association (APA), the American Pediatric Society (APS), and the Society for Pediatric Research (SPR).

“The acceptance of the abstract for presentation at the PAS meeting is great news and we are looking forward to the result of the study involving the use of Neo100, conducted by Dr Wagner and his team at the Medical University of Vienna. The PAS meeting is the largest Pediatric Research meeting in the world and this year’s meeting is expected to attract over 7,500 scientific attendees. Monivent will be present as one of the exhibitors”, says Karin Dahllöf, CEO of Monivent.

**For more information, please contact:**

Karin Dahllöf, CEO

Phone: +46 70 748 01 30

E-mail: [karin@monivent.se](mailto:karin@monivent.se)

Web: [www.monivent.se](http://www.monivent.se)

---

**Monivent AB** (“Monivent”) develops, manufactures and sells medical devices in order to improve the emergency care provided to newborns in need of respiratory support at birth. About three to six percent of all newborns end up in this critical situation and healthcare professionals today lack good tools to determine how effective this manual ventilation is. Monivent has developed equipment that measure the airflow to the child directly in the face mask via a sensor module that sends data wirelessly to an external monitor. The caregiver thereby receives immediate feedback, which enables necessary adjustments to support an effective but at the same time gentle treatment. The company is also marketing a product for simulation-based training on manikins, building on the same technology as the clinical product. The clinical product, Monivent Neo100, is not available for sale in the United States.